Patients and their caregivers are often left to navigate the confusing world of dementia by themselves, but Medicare is launching a new program to change that.
Alzheimer’s Disease
Posted inCost of Care
Can Medicare Afford to Foot the Bill for New Alzheimer’s Drugs?
Recent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.
Posted inCost of Care
How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation
Taking stock of the impact of the Aduhelm saga and Medicare’s decision to restrict coverage of the controversial treatment.
Posted inInsurance
Medicare’s Unprecedented Alzheimer’s Drug Decision
A doctor, a patient and a former federal official weigh in on Medicare’s recent move to restrict access to a new Alzheimer’s treatment.
Posted inCost of Care
The Aducanumab Aftermath: The Industry
How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Posted inCost of Care
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Posted inMental Health
The Aducanumab Aftermath: The Patient
One patient shares her hopes and concerns about a costly new Alzheimer’s drug.
Posted inCost of Care
The Aducanumab Aftermath: The Doctor
One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.
Posted inCost of Care
The FDA’s Pressure-Packed Alzheimer’s Drug Decision
The FDA weighs whether to approve a controversial new Alzheimer’s drug.
Posted inHealth Equity
Alzheimer’s Can Wreak Financial Havoc Years Before Diagnosis
Ezra Golberstein on new research that suggests negative financial consequences can start years before an Alzheimer’s diagnosis.